CN1429846A - 肿瘤新生血管特异性结合多肽与人α干扰素融合蛋白及制备 - Google Patents
肿瘤新生血管特异性结合多肽与人α干扰素融合蛋白及制备 Download PDFInfo
- Publication number
- CN1429846A CN1429846A CN 02139537 CN02139537A CN1429846A CN 1429846 A CN1429846 A CN 1429846A CN 02139537 CN02139537 CN 02139537 CN 02139537 A CN02139537 A CN 02139537A CN 1429846 A CN1429846 A CN 1429846A
- Authority
- CN
- China
- Prior art keywords
- ifn
- ngr
- interferon
- cell
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
组别 | 只数 | 肿瘤组织中IFNα浓度pg/g | 血清中IFNα浓度pg/ml | 瘤中浓度/血清中浓度(%) |
NS组 | 4 | 0 | 0 | |
普通干扰素组 | 5 | 0 | 298.6±52.3 | 0 |
靶向干扰素组 | 5 | 254.5±78.2 | 314.2±55.8 | 80.9 |
组别 | 只数 | 血清中IFNα2apg/ml | 瘤组织IFNα2apg/g | 肺组织IFNα2apg/g | 肝组织IFNα2apg/g |
NS组 | 4 | 0 | 0 | 0 | 50.1±4.2 |
普通干扰素组 | 4 | 46.5±8.9 | 50.8±4.5 | 70.8±20.7 | 48.5±7.1 |
靶向干扰素组 | 4 | 69.3±20.8 | 93.3±27.9 | 77.6±12.9 | 66.6±12.1 |
血清 | 肿瘤 | 肺 | 肝 | |
靶向组/普通组×100% | 149 | 183.7 | 109.6 | 137.3 |
组别 | 鼠数/只 | 治疗天数 | ||||||||
0 | 4 | 8 | 12 | 16 | 20 | 24 | 28 | 32 | ||
对照 | 6 | 88.0±58.2 | 175.2±166.6 | 435.0±263.1 | 660.6±371.2 | 837.9±487.5 | 1103.5±551.9 | 1355.5±831.0 | 1870.0±886.0 | 2243.5±1155.4 |
普通IFN | ||||||||||
LH | 56 | 94.2±64.0 | 183.6±138.8 | 285.2±213.2 | 496.4±363.5 | 696.5±438.3 | 903.5±550.8 | 1267.9±602.6 | 1549.1±902.6 | 1594.1±525.8 |
85.6±44.2 | 70.4±19.4 | 101.9±40.3* | 176.3±49.3* | 286.3±124.9 | 324.7±151.8** | 324.8±127.3* | 549.6±181.0* | 614.6±260.8* | ||
靶向IFN | ||||||||||
L | 6 | 87.5±70.1 | 96.7±40.6 | 135.2±90.6* | 199.9±10.7* | 255.4±132.5* | 329.6±223.4**# | 520.3±381.5*# | 577.5±484.7*# | 900.8±471.9*# |
H | 6 | 87.4±27.7 | 86.8±71.2 | 99.1±38.4* | 169.5±40.7** | 208.7±100.1* | 239.6±117.0** | 285.7±168.7* | 393.4±278.0** | 492.7±342.1** |
组别 | 鼠数/只 | 治疗天数 | |||||||
4 | 8 | 12 | 16 | 20 | 24 | 28 | 32 | ||
对照 | 6 | - | - | - | - | - | - | - | - |
普通IFN | |||||||||
L | 5 | -4.8 | 34.4 | 24.9 | 16.9 | 18.1 | 6.46 | 17.2 | 28.9 |
H | 6 | 60.0 | 76.6 | 73.3 | 65.8 | 70.6 | 76.0 | 70.6 | 72.6 |
靶向IFN | |||||||||
L | 6 | 44.8 | 69.0 | 69.3 | 69.5 | 70.1 | 61.6 | 67.1 | 59.8 |
H | 6 | 50.5 | 77.2 | 74.3 | 75.1 | 78.3 | 78.9 | 79.0 | 78.0 |
组别 | 鼠数/只 | 治疗天数 | ||||||||
0 | 4 | 8 | 12 | 16 | 20 | 24 | 28 | 32 | ||
对照 | 5 | 71.7±41.5 | 101.9±58.5 | 125.9±57.7 | 161.6±94.2 | 169.0±108.2 | 214.6±64.1 | 257.9±84.1 | 360.8±251.8 | 392.8±244.2 |
普通IFN | ||||||||||
L | 5 | 64.0±57.8 | 75.5±50.4 | 83.7±62.5 | 96.6±71.0 | 116.6±82.5 | 126.8±74.4 | 141.4±28.5 | 153.7±38.0 | 181.5±82.5 |
H | 5 | 68.3±54.8 | 79.5±60.4 | 84.4±67.0 | 84.4±40.1 | 86.4±38.5 | 86.9±51.3** | 92.2±70.0** | 116.0±94.5 | 94.4±89.8* |
靶向IFN | ||||||||||
L | 5 | 67.5±16.2 | 53.9±22.6 | 52.7±38.5* | 70.9±28.2 | 79.3±28.4 | 97.9±45.8* | 98.4±27.8**# | 93.8±33.9*# | 90.4±31.1*# |
H | 6 | 66.3±33.5 | 47.9±6.2* | 47.8±14.8* | 59.5±16.8* | 62.3±24.3* | 79.3±52.0** | 66.5±34.7** | 77.7±33.3 | 72.8±48.0* |
组别 | 鼠数/只 | 治疗天数 | |||||||
4 | 8 | 12 | 16 | 20 | 24 | 28 | 32 | ||
对照 | 5 | - | - | - | - | - | - | - | - |
普通IFN | |||||||||
L | 5 | 25.9 | 33.5 | 40.2 | 31.0 | 40.9 | 45.2 | 57.4 | 53.8 |
H | 5 | 22.0 | 33.0 | 47.8 | 48.9 | 59.5 | 64.2 | 67.8 | 76.0 |
靶向IFN | |||||||||
L | 5 | 47.7 | 58.1 | 56.1 | 53.1 | 54.3 | 61.8 | 74.0 | 77.0 |
H | 6 | 53.0 | 62.0 | 63.2 | 63.1 | 63.0 | 74.2 | 78.5 | 81.5 |
组别 | 鼠数/只 | 治疗天数 | ||||
0 | 3 | 6 | 9 | 12 | ||
对照 | 7 | 262.3±117.8 | 826.9±243.1 | 1450.2±1036.3 | 2600.6±1477.1 | 3859.4±2316.0 |
普通IFN | ||||||
L | 7 | 232.7±86.3 | 680.1±155.0 | 969.0±665.0 | 1814.9±1171.8 | 3104.1±2026.0 |
M | 7 | 222.7±54.1 | 590.0±138.0* | 1067.2±307.4 | 1670.5±481.8 | 3330.9±1500.3 |
H | 7 | 224.5±71.0 | 514.4±241.8* | 977.8±309.6 | 2255.6±1320.7 | 3602.4±1933.1 |
靶向IFN | ||||||
L | 7 | 222.9±30.0 | 454.8±250.9* | 513.3±258.3* | 647.5±313.5** | 1126.9±269.5** |
M | 7 | 228.3±57.0 | 697.1±357.1 | 1243.4±734.0 | 2044.3±1066.7 | 1905.7±647.9 |
H | 7 | 231.0±116.8 | 493.1±294.6 | 928.2±353.1 | 1905.7±674.9 | 3754.2±1373.0 |
组别 | 鼠数/只 | |||||
0 | 3 | 6 | 9 | 12 | ||
对照 | 7 | - | - | - | - | - |
普通IFN | ||||||
L | 7 | 0 | 17.7 | 33.1 | 30.2 | 19.6 |
M | 7 | 0 | 28.6 | 26.4 | 35.8 | 13.7 |
H | 7 | 0 | 37.8 | 32.5 | 13.3 | 6.65 |
靶向IFN | ||||||
L | 7 | 0 | 45.0 | 64.6 | 75.1 | 70.8 |
M | 7 | 0 | 15.7 | 14.3 | 21.4 | 20.6 |
H | 7 | 0 | 40.4 | 36.0 | 26.7 | 2.72 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02139537 CN1212337C (zh) | 2002-11-21 | 2002-11-21 | 肿瘤新生血管特异性结合多肽与人α干扰素融合蛋白及制备 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02139537 CN1212337C (zh) | 2002-11-21 | 2002-11-21 | 肿瘤新生血管特异性结合多肽与人α干扰素融合蛋白及制备 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1429846A true CN1429846A (zh) | 2003-07-16 |
CN1212337C CN1212337C (zh) | 2005-07-27 |
Family
ID=4750127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02139537 Expired - Fee Related CN1212337C (zh) | 2002-11-21 | 2002-11-21 | 肿瘤新生血管特异性结合多肽与人α干扰素融合蛋白及制备 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1212337C (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100390202C (zh) * | 2005-11-21 | 2008-05-28 | 中国人民解放军第四军医大学 | 肿瘤新生血管特异性结合多肽与重组人Tum-5融合蛋白及其制备方法 |
CN100400664C (zh) * | 2005-09-06 | 2008-07-09 | 中国人民解放军第四军医大学 | 肿瘤血管导向肽与人干扰素α-2b的融合蛋白的制备方法 |
CN102286074A (zh) * | 2011-07-06 | 2011-12-21 | 苏州工业园区晨健抗体组药物开发有限公司 | 一种cd13靶向肽ngr及其应用 |
CN104479024A (zh) * | 2014-06-19 | 2015-04-01 | 中国人民解放军成都军区总医院 | 新型抗瘤融合肽及其用途 |
CN105111310A (zh) * | 2006-11-21 | 2015-12-02 | 雅培制药有限公司 | 抗nogo-66受体(ngr)的中和单克隆抗体及其用途 |
CN105296515A (zh) * | 2015-08-21 | 2016-02-03 | 四川大学华西医院 | 一种干扰素A2b与胶原结合结构域的融合蛋白及其制备方法和用途 |
-
2002
- 2002-11-21 CN CN 02139537 patent/CN1212337C/zh not_active Expired - Fee Related
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100400664C (zh) * | 2005-09-06 | 2008-07-09 | 中国人民解放军第四军医大学 | 肿瘤血管导向肽与人干扰素α-2b的融合蛋白的制备方法 |
CN100390202C (zh) * | 2005-11-21 | 2008-05-28 | 中国人民解放军第四军医大学 | 肿瘤新生血管特异性结合多肽与重组人Tum-5融合蛋白及其制备方法 |
CN105111310A (zh) * | 2006-11-21 | 2015-12-02 | 雅培制药有限公司 | 抗nogo-66受体(ngr)的中和单克隆抗体及其用途 |
CN102286074A (zh) * | 2011-07-06 | 2011-12-21 | 苏州工业园区晨健抗体组药物开发有限公司 | 一种cd13靶向肽ngr及其应用 |
CN102286074B (zh) * | 2011-07-06 | 2013-09-11 | 苏州工业园区晨健抗体组药物开发有限公司 | 一种cd13靶向肽ngr及其应用 |
CN104479024A (zh) * | 2014-06-19 | 2015-04-01 | 中国人民解放军成都军区总医院 | 新型抗瘤融合肽及其用途 |
CN105296515A (zh) * | 2015-08-21 | 2016-02-03 | 四川大学华西医院 | 一种干扰素A2b与胶原结合结构域的融合蛋白及其制备方法和用途 |
CN105296515B (zh) * | 2015-08-21 | 2018-11-06 | 四川大学华西医院 | 一种干扰素A2b与胶原结合结构域的融合蛋白及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN1212337C (zh) | 2005-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3825467B2 (ja) | インターロイキン―7を用いた選定免疫療法 | |
CN1763093A (zh) | 含有hiv转导结构域的生存素突变体及制备方法和应用 | |
CN1124491A (zh) | 干细胞增生的抑制剂及其应用 | |
JPH06508039A (ja) | 抗腫瘍治療のためのサイトカインを発現する組換え型欠損アデノウイルス | |
JPH04501421A (ja) | 血小板産生刺激薬剤のためのil―7の使用 | |
CN1284134A (zh) | 利用毕赤氏酵母表达系统生产抗生血管蛋白质∶制管张素,内抑制素或静息蛋白的方法 | |
EA015510B1 (ru) | Способ увеличения количества мононуклеарных клеток у субъекта, страдающего раком, и используемая для этого фармацевтическая комбинация | |
CN1212337C (zh) | 肿瘤新生血管特异性结合多肽与人α干扰素融合蛋白及制备 | |
CN1142186A (zh) | 用白介素-10激活外周血单核细胞的细胞溶解活性 | |
WO2020103777A1 (zh) | 白介素21蛋白(il21)突变体及其应用 | |
CN100341897C (zh) | 肿瘤新生血管特异性结合多肽CRGDC与新型重组人肿瘤坏死因子nrhTNF融合蛋白及制备方法 | |
FR2615737A1 (fr) | Preparation et utilisation d'interferon-gamma | |
CN105968189A (zh) | B/t淋巴细胞弱化因子免疫原多肽及其用途 | |
CN113956344A (zh) | 一种新型治疗肝癌的fgf类似物及其应用 | |
CN1405185A (zh) | 肿瘤血管导向性与新型重组人肿瘤坏死因子融合蛋白及制备 | |
CN1800218A (zh) | 肿瘤新生血管特异性结合多肽与重组人Tum-5融合蛋白及其制备方法 | |
CN101096384A (zh) | 一种抗肿瘤融合蛋白的制备方法及其应用 | |
CN1177057C (zh) | 病毒载体与人肿瘤抑制基因的重组体及其应用 | |
JPS58107197A (ja) | ツモアネクロシスフアクタ−の製造方法 | |
CN106540253A (zh) | cGAMP及其衍生物在制备抗肿瘤疫苗中的应用 | |
CN87104270A (zh) | 改进的融合方法 | |
CN1261372A (zh) | 天然抗肿瘤性或抗病毒性物质及其用途 | |
CN101074266A (zh) | 转导肽-人源粒细胞集落刺激因子融合蛋白及其药物组合物 | |
CN87104365A (zh) | 改进的融合产物 | |
CN1418633A (zh) | 一种以20(s)-原人参二醇为有效成分的抗癌辅助药物及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHANXI KYRSHU SCIENCE & TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: THE FOURTH MILITARY MEDICAL UNIVERSITY OF P.L.A. Effective date: 20050107 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050107 Address after: 710075 New Era Hotel, 19 high tech Zone, Shaanxi, Xi'an Applicant after: Shaanxi Jiuzhou Technology Co.,Ltd. Address before: 710032 No. 17 West Changle Road, Shaanxi, Xi'an Applicant before: THE FOURTH MILITARY MEDICAL University |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANXI KYRSHU BIOLOGICAL MEDICINE SCIENCE + TECHNO Free format text: FORMER OWNER: SHANXI JIUZHOU BIOLOGY SCIENCE AND TECHNOLOGY CO., LTD. Effective date: 20091113 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: SHANXI JIUZHOU BIOLOGY SCIENCE AND TECHNOLOGY CO., Free format text: FORMER NAME: SHANXI KYRSHU SCIENCE CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: No. six, No. 196, science and technology zone, Xi'an hi tech Zone, Shaanxi Patentee after: SHAANXI JIUZHOU BIOTECHNOLOGY Co.,Ltd. Address before: 19 times hotel, new epoch zone, Xi'an hi tech Zone, Shaanxi Patentee before: Shaanxi Jiuzhou Technology Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20091113 Address after: No. six, No. 196, science and technology zone, Xi'an hi tech Zone, Shaanxi Patentee after: Shanxi GeoBiopharma Corp. Address before: No. six, No. 196, science and technology zone, Xi'an hi tech Zone, Shaanxi Patentee before: SHAANXI JIUZHOU BIOTECHNOLOGY Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: SHAANXI JIUZHOU BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: SHAANXI JIUZHOU BIOMEDICINE PARK Effective date: 20130625 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20130625 Address after: 710065 No. six, No. 196, hi tech Zone, Shaanxi, Xi'an Patentee after: SHAANXI JIUZHOU BIOTECHNOLOGY Co.,Ltd. Address before: 710065 No. six, No. 196, hi tech Zone, Shaanxi, Xi'an Patentee before: Shanxi GeoBiopharma Corp. |
|
ASS | Succession or assignment of patent right |
Owner name: SHAANXI JIUZHOU BIOMEDICINE PARK Free format text: FORMER OWNER: SHAANXI JIUZHOU BIOTECHNOLOGY CO., LTD. Effective date: 20130805 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20130805 Address after: 710065 No. six, No. 196, hi tech Zone, Shaanxi, Xi'an Patentee after: Shanxi GeoBiopharma Corp. Address before: 710065 No. six, No. 196, hi tech Zone, Shaanxi, Xi'an Patentee before: SHAANXI JIUZHOU BIOTECHNOLOGY Co.,Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160525 Address after: 403, room four, building 196, Kyushu science and Technology Park, No. six, 710065 hi tech Zone, Xi'an, Shaanxi Patentee after: SHAANXI SHENZHOU BIOTECHNOLOGY CO.,LTD. Address before: 710065 No. six, No. 196, hi tech Zone, Shaanxi, Xi'an Patentee before: Shanxi GeoBiopharma Corp. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050727 Termination date: 20181121 |